Taiyen Biotech Co (TPE:1737) Change In Receivables: NT$140 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1737 Taiyen Biotech Co Ltd TPE:1737
83 GF Score
Price NT$30.65
GF Value NT$31.14
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Taiyen Biotech Co Change In Receivables?

Taiyen Biotech Co TPE:1737 83 Change In Receivables is NT$140 Mil as of Jun. 2026. GuruFocus rates TPE:1737 with a GF Score™ of 83/100 and a GF Value™ of NT$31.14 (Fairly Valued). The stock has 2 warning signs investors should review.

Taiyen Biotech Co's change in receivables for the quarter that ended in Jun. 2026 was NT$33 Mil. It means Taiyen Biotech Co's Accounts Receivable declined by NT$33 Mil from Mar. 2026 to Jun. 2026 .

Taiyen Biotech Co's change in receivables for the fiscal year that ended in Dec. 2025 was NT$-16 Mil. It means Taiyen Biotech Co's Accounts Receivable increased by NT$16 Mil from Dec. 2024 to Dec. 2025 .

Taiyen Biotech Co's Accounts Receivable for the quarter that ended in Jun. 2026 was NT$104 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Taiyen Biotech Co's Days Sales Outstanding for the three months ended in Jun. 2026 was 12.28.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Taiyen Biotech Co's liquidation value for the three months ended in Jun. 2026 was NT$557 Mil.

Taiyen Biotech Co  (TPE:1737) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Taiyen Biotech Co's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=103.511/769.009*91
=12.28

2. In Ben Graham's calculation of liquidation value, Taiyen Biotech Co's accounts receivable are only considered to be worth 75% of book value:

Taiyen Biotech Co's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1965.663-1669.438+0.75 * 103.511+0.5 * 366.181
=557

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiyen Biotech Co Change In Receivables Related Terms

Taiyen Biotech Co Change In Receivables Historical Data

* Premium members only.

The historical data trend for Taiyen Biotech Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiyen Biotech Co Change In Receivables Chart

Taiyen Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -216.74 107.32 -86.51 80.65 -16.07

Taiyen Biotech Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.56 2.33 32.40 71.52 33.29
TPE:1737
83GF Score
Taiyen Biotech Co Ltd TPE:1737
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiyen Biotech Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$140 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of NT$140 Mil mean?
Taiyen Biotech Co (TPE:1737) has a Change In Receivables of NT$140 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Taiyen Biotech Co and its competitors.
Is Taiyen Biotech Co's Change In Receivables too high?
Taiyen Biotech Co's current Change In Receivables is NT$140 Mil. Overall, Taiyen Biotech Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiyen Biotech Co's Change In Receivables compare to PG and CL?
Taiyen Biotech Co's Change In Receivables of NT$140 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Consumer Packaged Goods company?
A good Change In Receivables depends on the Consumer Packaged Goods industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Taiyen Biotech Co and its competitors. Taiyen Biotech Co's current Change In Receivables is NT$140 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiyen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.14, compared to a current price of NT$30.65 — trading 1.6% below its estimated fair value. The current Change In Receivables is NT$140 Mil. Taiyen Biotech Co's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current Change In Receivables is NT$140 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?

Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be undervalued. The current stock price of NT$30.65 is trading 1.6% below its estimated GF Value™ of NT$31.14. GuruFocus considers Taiyen Biotech Co to be Fairly Valued.

Key valuation signals for TPE:1737:

  • Change In Receivables: NT$140 Mil
  • GF Value™: NT$31.14 vs. price of NT$30.65 (1.6% below fair value)
  • GF Score™: 83/100 with 2 warning signs

No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiyen Biotech Co Business Description

Address No. 297, Section 1, Chien-Kang Road, South District, Tainan, TWN
Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.
83GF Score

Get the complete analysis for TPE:1737

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.65
Price
NT$31.14
GF Value